IP Library Granted Patent US 8,513,182
Granted Patent B2
US 8,513,182 · App. 13/397,553 · Granted Aug 20, 2013

Natural polypeptides for oral health care

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,513,182
App. No.
13/397,553
Granted
Aug 20, 2013
Kind
B2
Abstract

The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and Statherin fusion proteins (STAT-LF) along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.

Claims (20)

1. A fusion protein that inhibits bacterial growth in the oral cavity, said fusion protein comprising a lysine form of a Lactoferrin polypeptide and a Statherin polypeptide, wherein said fusion protein is encoded by a nucleic acid having the sequence of SEQ ID NO. 10; SEQ ID NO. 11; or SEQ ID NO. 13, or a nucleic acid having at least 95% identity thereto that encodes a fusion protein having the activity of inhibiting bacterial growth in the oral cavity.

2. A composition comprising a fusion protein that inhibits bacterial growth in the oral cavity, said fusion protein comprising:

i. a lysine form of a Lactoferrin polypeptide; and

ii. a Statherin polypeptide, wherein said fusion protein is encoded by a nucleic acid having the sequence of SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:13 or a nucleic acid having at least 95% identity thereto that encodes a fusion protein having the activity of inhibiting bacterial growth in the oral cavity.

3. The composition of claim 2 , wherein the fusion protein is substantially purified.

4. The composition of claim 2 , wherein the composition further comprises an ingredient selected from a pharmaceutically acceptable excipient, a surfactant or surfactant-like molecule, an antibacterial agent, an antimicrobial agent, an antifungal agent or combinations thereof.

5. The composition of claim 4 , wherein the surfactant is sodium lauryl sulfate.

6. A method for inhibiting bacteria in the oral cavity comprising administering an effective amount of a composition comprising a fusion protein that inhibits bacterial growth in said oral cavity, said fusion protein comprising:

i. a lysine form of a Lactoferrin polypeptide; and

ii. a Statherin polypeptide, wherein said fusion protein is encoded by a nucleic acid having the sequence of SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:13 or a nucleic acid having at least 95% identity thereto that encodes a fusion protein having the activity of inhibiting bacterial growth in the oral cavity to a patient in need thereof.

7. The method of claim 6 , wherein the fusion protein is substantially purified.

8. The method of claim 6 , wherein the composition further comprises an ingredient selected from a pharmaceutically acceptable excipient, a surfactant or surfactant-like molecule, an antibacterial agent, an antimicrobial agent, an antifungal agent or combinations thereof.

9. The method of claim 8 , further comprising administering an effective amount of the surfactant or surfactant-like molecule to allow the composition to penetrate biofilm.

10. A method for the treatment or prevention of an oral health condition comprising administering an effective amount of a composition comprising a fusion protein that inhibits bacterial growth in said oral cavity, said fusion protein comprising:

i. a lysine form of a Lactoferrin polypeptide; and

ii. a Statherin polypeptide, wherein said fusion protein is encoded by a nucleic acid having the sequence of SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:13 or a nucleic acid having at least 95% identity thereto that encodes a fusion protein having the activity of inhibiting bacterial growth in the oral cavity to a patient in need thereof.

11. The method of claim 10 , wherein the oral health condition is selected from dental caries, periodontal disease, dental plaque and inflammation of the oral cavity.

12. The method of claim 10 , wherein the fusion protein is substantially purified.

13. The method of claim 10 , wherein the composition further comprises an ingredient selected from a pharmaceutically acceptable excipient, a surfactant or surfactant-like molecule, an antibacterial agent, an antimicrobial agent, an antifungal agent or combinations thereof.

14. The method of claim 10 , further comprising administering an effective amount of a surfactant or surfactant-like molecule to allow the composition to penetrate biofilm.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Sep 5, 2013
From: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 031170/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2013
From: FINE, DANIEL; RAMASUBBU, NARAYANAN
To: THE UNIVERSITY OF MEDICINE AND DENTISTRY
Reel/Frame 030153/0155 →